Esophageal Squamous Cell Carcinoma
About
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | PD-L1 >= 1% | Esophageal Squamous Cell Carcinoma | Ipilimumab, Nivolumab | |
| Sensitivity (+) | PD-L1 >= 1% | Esophageal Squamous Cell Carcinoma | Cisplatin, Fluorouracil, Nivolumab | |
| Sensitivity (+) | PD-L1 >= 1% | Esophageal Squamous Cell Carcinoma | Ipilimumab, Nivolumab | |
| Sensitivity (+) | PD-L1 >= 1% | Esophageal Squamous Cell Carcinoma | Cisplatin, Fluorouracil, Nivolumab | |
| Sensitivity (+) | PD-L1 >= 1% | Esophageal Squamous Cell Carcinoma | Cisplatin, Fluorouracil, Nivolumab | |
| Sensitivity (+) | PD-L1 >= 1% | Esophageal Squamous Cell Carcinoma | Fluorouracil, Nivolumab, Oxaliplatin |